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Abstract: Improved diagnosis and treatment regimens have resulted in greater longevity for
men with prostate cancer. This has led to an increase in both androgen deprivation therapy (ADT)
use and duration of exposure, and therefore to its associated adverse effects, such as sexual
dysfunction, osteoporosis, reduced muscle mass, increased fat mass, and increased incidence of
cardiovascular disease and type 2 diabetes. Given that the adverse effects of ADT are systemic,
often debilitating, and difficult to treat, efforts continue in the development of new strategies
for long-term management of prostate cancer. The PubMed database was searched to select
trials, reviews, and meta-analyses in English using such search terms as “prostate cancer” and
“androgen deprivation therapy”, “cardiovascular risk”, “lean body mass”, “exercise”, and “diet”.
The initial searches produced 379 articles with dates 2005 or more recent. Articles published
after 2004 were favored. This review utilizes the latest data to provide a status update on the
effects of exercise and diet on patients with prostate cancer, focusing on ADT-associated side
effects, and it discusses the evidence for such interventions. Since the evidence of large-scale
trials in patients with prostate cancer is missing, and an extrapolation of supporting data to all
patient subgroups cannot be provided, individualized risk assessments remain necessary before
the initiation of exercise and diet programs. Exercise, diet, and nutritional supplementation
interventions have the potential to provide effective, accessible, and relatively inexpensive
strategies for mitigating ADT-associated toxicities without introducing additional adverse effects.
Keywords: androgen deprivation therapy, ADT, diet, exercise, nutrition, prostate cancer, dietary
supplements
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Prostate cancer is the most frequently diagnosed cancer among men in developed
countries.1 Widespread adoption of programs to screen for prostate-specific antigen
has revolutionized the diagnosis and treatment of prostate cancer. Early detection and
development of new treatment options have improved outcomes, increasing 5-year
survival from 67.8% to 99.7% over the past 25 years, with 10- and 15-year survival
presently at 99% and 94%, respectively.2 Thus, prostate cancer has moved from an
aggressive, often fatal, disease to a chronic condition requiring comprehensive management strategies to maintain patients’ quality of life (QoL).
Androgen deprivation therapy (ADT) has long been the frontline treatment for
advanced prostate cancer.3–8 Indeed, over a third of the roughly 3 million men in the
USA presently diagnosed with prostate cancer have received or are receiving ADT.2
Although ADT has been found to improve the overall survival, it is also associated with
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adverse side effects, including sexual dysfunction, gynecomastia, hot flashes, o steoporosis, cognitive defects, reduced
muscle mass, increased fat mass, and increased incidence of
both cardiovascular disease and type 2 diabetes.9–12
Although earlier diagnosis and treatment have greatly
extended patient longevity, they have also led to a considerably
longer duration of ADT. An alternative, intermittent ADT has
been proposed to mitigate the adverse effects of continuous
ADT with the premise that it will not impact efficacy.13,14
Although intermittent ADT offers some relief from the side
effects of continuous ADT, in particular during treatment
pauses, comprehensive management plans aimed at helping
patients cope with the long-term effects of ADT throughout
all phases of therapy are essential, but are often missing.
Ninety percent of the patients with prostate cancer in
the USA are aged 60 years or older,2 a population known
to be at high risk for cardiovascular and diabetic comorbidities.15 Exercise and diet programs are important factors
in reducing the risks of these conditions.16 Exercise and
improved diet, therefore, have the potential to improve the
QoL and also possibly the long-term survival of patients
with prostate cancer (who may or may not be on ADT).17,18
Some clinical trial data, including that from multiple
randomized controlled trials, have demonstrated the ability of exercise and dietary modifications to ameliorate
ADT-associated adverse effects, and patients and physicians need to be informed about these nonpharmacologic
approaches. Here, we review recent studies of exercise
and nutritional interventions to assess their potential
impact on the outcomes in patients with prostate cancer
receiving ADT.
We searched the PubMed database to select trials,
reviews, and meta-analyses in English in the last 10 years
(2005–2015) using search terms “prostate cancer and cardiovascular diseases/diet/exercise/sexual dysfunction”, “androgen deprivation therapy and diet/exercise/bone”, and “cancer
and body composition”. The initial searches produced 3,863
records after the removal of duplicates. Figure 1 shows the
flowchart of manuscript selection.

Impact of exercise on patients with
prostate cancer
Exercise, prostate cancer, and mortality risk
The beneficial impact of regular physical activity on many
chronic ailments, including cardiovascular disease, osteoporosis, diabetes, obesity, fatigue, and depression, has been
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reported in many studies, not least in the 1996 US Department of Health and Human Services Report of the Surgeon
General.16 There is a paucity of good data with respect to
the effect of exercise on the mortality of men with prostate
cancer. Studies of cancer (including prostate cancer) have
shown that there is a link between increased physical activity
and improved physical functioning in cancer survivors. For
example, the Reach out to Enhance Wellness study enrolled
641 elderly (mean age, 73 years), sedentary, overweight, or
obese (mean body mass index [BMI], 29 kg/m2) cancer survivors (including 94 prostate cancer survivors) and utilized
a home-based diet and exercise intervention. The Reach out
to Enhance Wellness intervention consisted of workbooks,
equipment, and quarterly newsletters, endorsing 15 minutes of strength training every other day and 30 minutes of
endurance exercise daily to evaluate the effects on physical
function. The intervention produced a decrease in the rate of
physical function decline, according to various self-reported
measures, including the Medical Outcomes Study Short
Form-36 (SF-36); the intervention also produced a decrease
in BMI compared with the control (delayed intervention)
population.19,20
Kenfield et al17 studied a population of 2,705 male health
care professionals (mean age at prostate cancer diagnosis
about 70 years) with nonmetastatic prostate cancer and
found that those participating in vigorous physical activity
(metabolic equivalent task [MET] value21 ≥6) for a duration
≥3 hours/week demonstrated a 49% lower risk of all-cause
mortality and a 61% lower risk of death specifically from
prostate cancer, compared with men who did <1 hour/week
of vigorous activity. MET value is a way of defining the
energy cost of physical activity in adults, and examples
range from meditation (1 MET), stationary bike or jogging
(7 METs), playing squash (12 METs), running up stairs (15
METs) to running at 14 mph (25 METs).17 The men engaging in nonvigorous exercise (MET value <6, eg, walking
at a normal to very brisk pace) ≥90 minutes/week had an
all-cause mortality risk 46% less than those who walked <90
minutes/week. There was, however, no statistically significant difference between nonvigorous exercise and walking
with respect to prostate cancer-specific mortality.17 Other
studies in large populations of men who were cancer-free at
enrollment, however, have shown no significant association
between physical activity, body weight, and waist girth and
prostate cancer risk,22,23 although Patel et al23 suggest that
physical activity may be associated with reduced risk of
aggressive prostate cancer.23
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Identification
Records identified through database searching
(n=4,367)
Records after duplicates removed
(n=3,868)

Screening
Records screened
(n=3,868)
Records excluded based on
title and abstract screening
Nonprostate cancer
ADT-unrelated drug clinical trials
Animal studies/cell biology/biochemistry
(n=3,487)

Eligibility
Full-text articles assessed for eligibility
(n=381)
Full-text articles excluded
Cardiovascular/diet/supplement only
Not directly relevant to review topic
(n=309)

Additional articles identified
through references (pre-2005)
(n=29)

Included
Included in final review
(n=101)
Figure 1 Flow diagram showing manuscript selection process.
Abbreviation: ADT, androgen deprivation therapy.

Strength, lean body mass, and
functional ability
A systematic review of ten studies (five randomized and five
uncontrolled clinical trials) examined the effects of exercise
on patients receiving ADT.24 Study populations included both
patients with metastatic and nonmetastatic prostate cancer,
with mean ages ranging from 63 to 72 years, and with ADT
duration of 4 to >44 months. The number of patients on
ADT undergoing exercise interventions ranged from five in
a pilot study25 to 74.26 Although most interventions included
two to six exercise-based sessions per week for 24 weeks,
the interventions were heterogeneous, varying in duration,
frequency, intensity, and degree of supervision. Despite this
heterogeneity, the evidence demonstrated that physical performance was improved by exercise. Randomized controlled
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trials found exercise to be consistently beneficial for muscular
performance: reported as increases in muscular strength and
increases in upper and lower limb strength, compared with the
control population (see, eg, Bourke et al27 and Galvão et al28).
Although one study found improvement in cardiovascular fitness27 and others showed improvements in 400-m29 or 6-minute
walk times,25 still other studies showed no improvement in
6-minute walk times or in cardiorespiratory fitness.30,31
Body composition is a component of many studies investigating exercise effects on prostate cancer patients on ADT,24
and resistance training has been shown to either increase lean
body mass28 or reduce its decline26 in randomized controlled
trials. Other uncontrolled studies have shown increased
lean body mass,29 decreased BMI, or decreased weight with
resistance exercise.29,32 The data on adiposity are not clear,
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as some studies report an adiposity reduction,30,33 whereas
others report no differences between exercising and control
groups.26–28

Fatigue
Fatigue measurements, assessed by patient-reported questionnaires, such as the Functional Assessment of Cancer
Therapy-Fatigue (FACT-F) 34 or the Functional Assessment of Chronic Illness Therapy-Fatigue,35 are frequently
assessed together with exercise outcomes in these studies.24,36,37 In general, the evidence is equivocal as to whether
exercise helps diminish patient-reported fatigue. Some
studies show clinically meaningful improvement versus
controls,26,27,33,38 whereas another failed to show benefit.30
Some uncontrolled studies show benefit; for example, Hanson et al29 showed that in 17 black men on ADT, strength
training reduced fatigue perception by 38%, which exceeds
changes reported in other cancer survivor studies. On the
other hand, for example, Hansen et al25 found that exercise
training in ten men with prostate cancer produced no significant difference in fatigue between those on ADT and those
who were not. Neither of these studies was large enough
to allow statistically meaningfully comparisons to be made
between the groups.

QoL
Many controlled and uncontrolled studies report that
physical activity improves aspects of patient-reported QoL.
The most widely used measures for self-reported general and
psychosocial QoL (mental health/emotional well-being) are
the Medical Outcomes Study 12-item Short Form (SF-12)
and the SF-36.24,39 A 3-month exercise program consisting
of aerobic and resistance exercises produced clinically significant improvement in the SF-36 scores of 32 men with
prostate cancer starting ADT, compared with 31 men starting ADT on usual care but not exercising.38 Likewise, in a
pilot study, resistance exercise training sessions three times
a week for 12 weeks produced clinically significant prostate cancer-specific improvement in the QoL for five men
on ADT, compared with those on usual care, as measured
by the FACT-Prostate scale.25 In contrast, however, Cormie
et al36 studied 20 men with bone metastases secondary to
prostate cancer and found no significant between-group differences in QoL or psychological distress comparing those
who underwent a 12-week resistance exercise program and
those on usual care.
Interestingly, a study of 66 prostate cancer survivors
compared home-based aerobic training with home-based

136

submit your manuscript | www.dovepress.com

Dovepress

resistance training and found that after 6 months, the aerobic
group had undertaken significantly more physical activity
than the resistance training group, although fatigue and QoL
were not significantly different between the two groups.31 This
suggests that aerobic exercise may be more attractive to the
prostate cancer population than resistance exercises. This
has implications as aerobic exercise is anticipated to have a
greater impact on cardiovascular health, whereas resistance
exercise is more associated with increases in muscular
strength and lean body mass.

Cardiovascular disease
In 2006, the Surveillance, Epidemiology, and End Results
Medicare study reported an observed 11% increase in myocardial infarction risk and a 16% increased risk of coronary
heart disease and death from cardiac arrest in an observational
study of prostate cancer patients receiving ADT, versus those
not on hormone therapy (n=73,196).3 In a later study of men
in the Veterans Healthcare Administration database, ADT was
also found to be associated with stroke.40 These reports, along
with observational evidence from several additional studies
linking ADT to an increased risk of cardiovascular events,
prompted the US Food and Drug Administration to issue a
communication in 2010 requiring that manufacturers of drugs
for ADT include a warning label citing an increased risk of
diabetes and certain cardiovascular diseases (eg, heart attack,
sudden cardiac death, and stroke) with their use.41 The link
between ADT and cardiovascular events remains somewhat
controversial; however, as subsequent studies indicate that
although ADT appears to be linked to an increased risk for
cardiovascular events, it is not associated with higher rates
of related mortality.11,42
Although there are no studies to date that are specifically
powered to evaluate the effect of exercise on ADT-mediated
cardiovascular events, there is a large body of evidence supporting the role of physical activity in the prevention and
management of cardiovascular disease in broader populations.43–46 Many plausible mechanisms could be involved in
the protective effects of physical activity, including protection against atherosclerosis, improvement of plasma lipid
and lipoprotein profile, dilation of peripheral blood vessels/
attenuation of sympathetic nervous activity leading to reduction in blood pressure, adaptations to coronary circulation,
reduction in thromboses due to enhanced fibrinolysis, and
decrease in the aggregation and adhesion of platelets.16,47,48 By
extension, it seems likely that implementation of an exercise
program would help mitigate the cardiovascular risk factors
associated with ADT, although further research is necessary.
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Bone health
Bone density reduction is a serious consequence of ADT, with
the frequency of osteoporosis and osteopenia being directly
proportional to treatment duration.49–51 This is particularly
significant in men, as a high mortality rate (up to 37.5%) is
associated with minimal trauma fractures.52 The greatest loss
of bone mineral density occurs in the first year of ADT, with
noticeable changes seen within months as androgen levels
decline.53 Many epidemiologic studies have reported that low
body weight and low BMI are risk factors for diminished bone
mineral density and fragility fracture. An explanation for the
correlation of higher body weight and bone resilience is that
this may be due to increased mechanical load on the bones in
heavier persons stimulating an increase in bone mineral density.54,55 There is considerable evidence that physical activities
involving mechanical loading, such as resistance training and
high-impact load-bearing exercises, are beneficial for bone
health in the general population.16,52 In contrast to this view,
however, a recent study of a heterogeneous cohort of 8,833
men aged 18–64.9 years used computed tomography to show
an inverse relationship between adiposity (BMI and visceral
and subcutaneous adiposity) and bone quality.56
Despite the known effects of ADT on bone health, there
is a paucity of data available regarding the impact of exercise
on the bone health of patients receiving ADT. Recently, a
randomized controlled study in 63 men with prostate cancer
examined the effect of moderate- to high-intensity aerobic
and resistance exercises in preventing ADT-associated
toxicity in the first 3 months of treatment and found no significant difference in bone mineral density loss and in blood
biomarkers of bone turnover between the exercise and usual
care groups.38 The authors speculated that the efficacy of
exercise-based interventions will likely require incorporation of targeted, high-impact activities that provide skeletal loading, such as jumping and hopping. Indeed, similar
results have been observed in resistance training studies in
older men and women, where only high-intensity, and not
moderate-intensity, strength training resulted in increased
bone mineral density.57–59
A clinically important issue is whether high-impact or
moderate- to high-intensity exercise might put patients with
prostate cancer at risk of fracture, particularly in 70%–80%
of advanced prostate cancer patients who have bone metastases.60 The risk increases further given the effect that ADT
has on bone health. For example, a study of 19,079 Canadian
men with prostate cancer demonstrated a 65% increased fragility risk for those on at least 6 months of ADT, compared
with those not on ADT.61 Exercise, therefore, is commonly
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not recommended for this population, due to fears over fragility and potential fracture. However, a recent randomized,
preliminary, 12-week study of targeted, moderate- to highintensity exercise in 20 prostate cancer patients with bone
metastases, found that the exercise was well tolerated, with
93% patient compliance and no reported adverse events.36
This provides initial evidence that supervised resistance exercise may be safe for prostate cancer patients with metastatic
bone disease, although the data from this trial showed that
the intervention made no significant changes to the patients’
bone mineral density. The supervised exercise did, however,
improve other measures, such as physical activity, muscular
strength, and lean body weight. More studies involving larger
numbers of subjects are required to build on these results.

Sexual dysfunction
About 30%–90% of prostate cancer patients have been
reported to experience adverse sexual side effects from their
care treatments.62–64 Sexual dysfunction can profoundly affect
patients’ QoL and lead to depression, loss of connection
with their partner, and decline in their identity as a man.62,64
Addressing ADT complications will likely play an important
role in improving the overall outcomes.
Kratzik et al65 observed that in healthy men aged 45–60
years (n=674), risk of severe erectile dysfunction was 83%
less among men who exercised ≥3,000 kcal/week, compared
with those who exercised ≤3,000 kcal/week. In two studies, Cormie et al38,66 examined the effect of moderate- to
high-intensity exercise (resistance and aerobic) over a
12-week intervention. Using the sexual function section
of the European Organization for Research and Treatment
of Cancer prostate cancer-specific module questionnaire,
the researchers found significant differences between the
usual care (nonexercise) group and the exercise group, with
the latter reporting maintenance of sexual activity and a
higher percentage of participants with a major interest in
sex (17.2% vs 0%, P=0.024).38,66 In-depth interviews with
18 men (mean age, 63.1 years) receiving ADT for prostate
cancer suggest that exercise may be helpful in alleviating
sexual dysfunction in a broader, less specific manner. The
role of exercise in mitigating the reduction in lean body
mass and muscular strength seen with ADT may be important in improving the subjects’ perceptions of their masculinity, which in turn leads to a better psychological frame
of mind with respect to their sexuality.67 Further research is
needed, but this preliminary data suggest that exercise may
be able to play a role in reducing ADT-associated sexual
dysfunction.
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Metabolic syndrome
ADT is associated with significant adverse metabolic effects,
including elevated serum triglycerides (≥150 mg/dL); fasting
serum glucose ≥100 mg/dL; weight gain, especially of the
abdomen; peripheral insulin resistance; and increased diabetes risk.3,9,40,68 These effects are characteristics of metabolic
syndrome and increase the risk of heart disease and stroke,
in addition to diabetes.69
We reviewed the data on cardiovascular fitness earlier,
and there is good evidence that exercise improves or mitigates the decline in lean body mass and decreases the BMI
of patients on ADT. There is also the additional evidence
that exercise may impact the overall all-cause mortality, of
which cardiovascular events are a large proportion. Exercise
that is considered desirable in a noncancer population is also
likely to show benefit in men with prostate cancer. Segal
et al26 reported that 12 weeks of resistance training in 155
men with prostate cancer and receiving ADT resulted in
significantly greater upper and lower body muscular fitness,
compared with those on usual (nonexercise) care; however,
waist circumference, BMI, or subcutaneous adiposity differences between groups were not significant.
Recently, two studies38,70 have shown that exercise-based
interventions are promising methods for reducing few ADTspecific metabolic effects. Results from a randomized pilot
study assessed the impact of over 6 months of combined
metformin, a low-glycemic-index diet, and exercise in 20
prostate cancer patients at ADT initiation and compared this
with 20 men who were on ADT alone. The metformin and
exercise group had decreased abdominal girth, weight, BMI,
and systolic blood pressure, compared with the group on
ADT treatment alone, although insulin-resistant biochemical
markers were not significantly different. In this small study,
however, it was not possible to separate the metformin and
dietary effects from the exercise components.70 In the study by
Cormie et al38, 63 prostate cancer patients were randomized
to receive either a 3-month aerobic and resistance exercise
program or usual care, concomitant to initiation of ADT.
Patients receiving the exercise-based intervention demonstrated significant reductions in ADT-associated metabolic
effects, including decreased whole body fat mass, trunk fat
mass, and percentage fat, compared with the usual care control
group. The ratio of total cholesterol to high-density lipoprotein
(HDL) cholesterol improved in the exercise group, which is
clinically significant, as this ratio is a common cardiovascular disease risk marker. There were no significant changes,
however, in other cardiovascular and metabolic biomarkers,
such as triglycerides, insulin and glucose levels, or glycated
hemoglobin.38
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Evidence from trials has also shown that ADT can cause
significant increases in HDL.38,71–73 A feature of ADT-associated
metabolic changes is that HDL is usually elevated, which is
not typical with metabolic syndrome (where HDL levels are
low).72,73 Potentially, HDL increases could be further amplified
by the addition of prescriptive exercise. Although these are
preliminary studies, they suggest that exercise may provide
some benefit in lessening the adverse metabolic effects of
ADT. Two randomized trials are presently being conducted to
investigate this further.74,75
C-reactive protein, an inflammation marker commonly
elevated in metabolic syndrome, showed a clinically meaningful reduction in a randomized controlled trial of exercise
in 57 men on ADT.28 Going forward, further study is required
to investigate the correlations between C-reactive protein
level and exercise.
Although the final verdict from large-scale trials is still
outstanding, exercise programs should be considered an
integral part of treatment for men with prostate cancer, as
they can provide low-cost, scalable, and widely accessible
strategies to help counter the systemic effects associated
with prostate cancer therapies, including ADT. Exercise
impacts patient well-being, both physical and psychological,
potentially leading to improved physical functioning and
survival.24,39,75–77 However, before a general recommendation
can be issued, treating physicians should exercise caution
when considering to institute exercise and diet programs, and
patients should be carefully assessed prior to any intervention.

Effect of nutrition and dietary
supplements on the complications
of ADT
Nutrition and dietary supplements
There is a lack of data on how nutritional adjustments might
affect ADT-associated adverse effects and the few studies
that have investigated the integration of either nutritional
counseling or modified diet have done so in conjunction with
another intervention, making it difficult to specifically assess
the impact of dietary changes.70,78 Given the similarities to
what is observed in postmenopausal women, however, some
researchers have made specific recommendations for lifestyle
modifications, including smoking cessation, moderation
of alcohol and caffeine intake, and supplementation with
vitamin D and calcium.79,80 As mentioned in the previous
section, a low-glycemic-index diet, regular exercise, and metformin treatment have been shown to significantly improve
abdominal girth, weight, BMI, and systolic blood pressure in
patients receiving ADT.70 Caffeine is also garnering research
as a method to potentially improve workout energy levels and
Research and Reports in Urology 2016:8
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duration and postworkout discomfort.81 Studies with prostate
cancer patients are lacking, although caffeine consumed
(0.16 mg/kg anhydrous caffeine) 1 hour before completing
a number of functional performance and exercise capacity
tests has been reported to increase the exercise capacity by
3.0% versus placebo in a randomized, double-blind crossover
study in 30 prostate cancer survivors. There was no significant
difference, however, in postexercise fatigue and perception
of exertion compared with placebo, nor in other functional
performance measures.82

Bone health
Despite the debilitating effects of osteoporosis observed
in men receiving ADT, few studies have examined two key
modulators of bone health in this population: vitamin D and
calcium. Bone density deterioration is known to occur shortly
after initiation of ADT.49,50 A meta-analysis of calcium and
vitamin D studies in women and men aged ≥50 years (92%
of study participants were women and those with secondary
osteoporosis were excluded) provided evidence that calcium
and vitamin D supplementation is associated with a reduced
rate of bone mineral density loss in the hip and the spine,
and also with decreased risk of fracture.83 On the basis of
this evidence, the European Association of Urology has
recommended that calcium and vitamin D supplements be
monitored both prior to and during ADT if serum concentrations fall below the lower limit of normal (normal range:
calcium, 2.2–2.6 nmol/L; vitamin D, 100–160 nmol/L).84
In its most recent guidelines, the European Association of
Urology recommends that a daily intake of ≥1,200 mg/day
of calcium and 1,000 IU of vitamin D may be useful for
improving bone mineralization in prostate cancer patients.84
The National Osteoporosis Foundation, on the other hand,
supports the Institute of Medicine guidelines recommending that men aged 50–70 years consume 1,000 mg/day of
calcium, and those ≥71 years, 1,200 mg/day of calcium.85,86
A systematic review of twelve clinical trials, however,
failed to find conclusive support for these recommendations
in prostate cancer patients receiving ADT, noting that the
frequently recommended daily doses of calcium (500–1,000
mg) and vitamin D (200–500 IU) were insufficient to prevent ADT-associated bone density loss.87 More recently, in a
prospective longitudinal study, Alibhai et al88 examined the
long-term effects of calcium and vitamin D supplementation
in 160 prostate cancer patients (mean age, 69 years), with and
without ADT. Vitamin D, but not calcium, was shown to provide some protection from bone density loss, especially in the
first year of ADT. It seems likely that the efficacy of vitamin
D and calcium supplementation may require implementation
Research and Reports in Urology 2016:8
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of concomitant exercise programs to stimulate bone accrual,
as discussed earlier.36,38,75

Fat and muscle mass
Although there are a number of randomized controlled trials
that have demonstrated exercise to be effective for reducing
fat mass in overweight older men,89 the absence of testosterone in men on ADT has proven to be a more difficult
challenge. It has been reported that during the early phase
of ADT, fat loss or maintenance of BMI can be achieved
through exercise alone.38,90 This concept remains controversial, however, as other studies have suggested that, in addition
to exercise, caloric restriction is required for consistent fat
loss in men.89,91
Loss of muscle mass, which has major consequences for
physical function and risk of metabolic disease, is a frequently
reported adverse effect of ADT.11 Resistance training has
consistently been associated with muscle hypertrophy in men
on ADT.28,31 This effect is likely to be amplified by appropriate nutritional supplementation, including protein, carbohydrates, and creatine monohydrate, as has been demonstrated
in studies of both younger and older men not on ADT.92
Recently, a meta-analysis of 14 randomized controlled trials
in a total of 626 adults showed an increase in weight loss,
lean body mass, and a decrease in visceral fat among men
receiving supplemental whey protein in combination with
resistance training.93 Although more studies are needed, the
potential for whey protein or another similar protein isolate
to mitigate the adverse effects of prostate cancer therapies
is considerable.

Fatigue
Encouraging data from a randomized, double-blind, phase
III trial of American ginseng (2,000 mg/day) found a statistically significant and clinically meaningful decrease in
cancer-related fatigue in 171 patients (4% of whom had
prostate cancer), compared with 170 patients on placebo.94
The primary endpoint was the Multidimensional Fatigue
Symptom Inventory-Short Form. American ginseng is the
first treatment option, besides exercise, to show efficacy in
addressing cancer-related fatigue, as no other drugs, including stimulants, have been proven to be effective. Interestingly,
similar to what was observed with exercise,38 greater benefits
were found in patients who started ginseng at the same time
as their cancer treatment, compared with patients who started
ginseng after treatment initiation. This suggests that treatment
with American ginseng should be started at the same time or
prior to ADT initiation; however, this needs to be confirmed
with a larger study population of patients with prostate cancer.
submit your manuscript | www.dovepress.com
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Cardiovascular disease
The impact of ADT on cardiovascular disease development
and progression remains contested in the literature. Regardless, heart disease is a leading cause of mortality in all men,
including those on ADT.42 Lifestyle changes, such as modifications to diet and exercise, may significantly affect cardiovascular disease risk in prostate cancer patients on ADT.18
Although it has not been studied in patients on ADT, fish
oil has been approved by the Food and Drug Administration for
use in lowering triglycerides.95 Correspondingly, the American
Heart Association recommends that individuals with heart
disease take 1,000 mg of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), the primary omega-3 fatty
acid components of fish oil, daily.96 Indeed, a large, randomized controlled trial (Japan EPA Lipid Intervention Study) in
18,645 Japanese subjects has shown synergistic effects between
omega-3 acids and statins in reducing serum triglycerides in

patients with high cholesterol.97,98 Interestingly, further subgroup analysis found that fish oil significantly reduced the
incidence of coronary artery disease in subjects with impaired
glucose metabolism (–22%), even greater than that observed
for subjects with normal glucose metabolism (–18%).97

Conclusions
The advent of prostate-specific antigen screening programs,
greater public awareness of prostate cancer, and improved treatment regimens have fundamentally altered the disease landscape.
A consequence of greater patient longevity is a more extended
exposure to ADT and its associated adverse effects. Given that
the adverse effects of ADT are systemic, often debilitating, and
difficult to treat, efforts are being made in the development of
new strategies for long-term management of prostate cancer.
As summarized in Table 1, exercise, diet, and nutritional
supplementation interventions have the potential to provide

Table 1 Adverse effects reported with ADT and potential lifestyle, supplemental, and prescription medication solutions
ADT-associated
adverse effects

Potential solutions
Exercise

Anemia

Bone loss

Fatigue

Hot flashes

Lipids and/or prediabetes
(elevated cardiovascular
risk)

Sarcopenia

Weight gain (visceral
adipose tissue
accumulation)

Diet

Drugs

• Primarily normochromic, normocytic anemia with ADT, thus no lifestyle or supplemental options available for
treatment99
• Asymptomatic in 90% of patients, so medication is rarely, if ever, needed99
Resistance exercise 2–3 times a week in combination with 1,000–1,200
• Prescription medication should be
mg of calcium and 800–1,000 IU of vitamin D (from food and/or
considered based on the duration of ADT
supplements)36,51,100
and documented severity of bone loss
Resistance exercise24,38
• Caffeine from beverages
(general stimulant)81
• American ginseng (2,000 mg/
day at 3%–5% ginsenosides)94
Maintaining a healthy weight may
No dietary supplement has
• Prescription medication can be effective
reduce the severity of vasomotor
demonstrated a consistent
(eg, megestrol acetate, venlafaxine) for
symptoms and moderate aerobic
benefit over placebo101
moderate-to-severe QoL – altering hot
exercise could also be beneficial
flashes101
Omega-3 fatty acids (EPA/DHA;
• ADT has controversial
• When appropriate, low-dose statin and/or
500 mg/dL or more) FDAcardiovascular risk data18
ezetimibe prescription treatment; low-dose
approved for hypertriglyceridemia
• Diet and exercise80
aspirin for those who qualify, based on
only (although studies lack clinical
• Abnormal glucose levels may
overall cardiovascular risk80
endpoints)95–98
respond to diet and exercise70
• When appropriate, prescription metformin
has preliminary data with ADT70
Resistance exercise 2–3 times per week in addition to calcium and
vitamin D recommended daily intake (as for bone loss)28,92
• Preliminary indirect evidence
suggests that whey protein
isolate (or another protein
isolate) at 20–25 g per day
could also assist with muscle
protein synthesis93
Diet and aerobic and resistance
Whey protein isolate may also
• Metformin (850 mg twice a day) has
exercise24,38
assist with appetite suppression93
preliminary data for weight loss with ADT70

Notes: Not all the adverse events listed in this table are discussed in this review. We refer the reader to the scientific literature for more detailed discussions of these.
Abbreviations: ADT, androgen deprivation therapy; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FDA, US Food and Drug Administration; IU, international
unit; QoL, quality of life.
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relatively inexpensive and accessible strategies for mitigating
many ADT-associated toxicities and are unlikely to introduce
additional adverse effects. However, since the evidence of
large-scale trials in patients with prostate cancer is missing, and an extrapolation of supporting data to all patient
subgroups cannot be provided, individualized risk assessments remain necessary before the initiation of exercise
and diet programs. The coordinated efforts of health care
professionals, including exercise physiologists and dieticians,
coupled with increased patient awareness, will be critical for
effective implementation of such intervention programs, and
future research would help to further our understanding of
the effectiveness of diet and exercise in this complex patient
population.
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